To better understand why some cancer patients struggle to fight off infections, Georgia Tech researchers have created tiny ...

When thinking about the immune system, most people think about B and T cells and how they can be trained to recognize ...

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

However, patients can survive without B cells. With solid tumors ... immunosuppressive microenvironment that "can shut down ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

“We're trying to target this pre-programmed subset of B cells,” Scharffenberger said. “If you're able to target them ...

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement ... including 51% of patients with ...

The team used synthetic hydrogels to recreate a microenvironment where B cells from human blood and tonsils can ... which failed to trigger the same response in cells from lymphoma survivors who ...

Should you invest in Bicara Therapeutics Inc? Click for more on BCAX's promising cancer treatment, but proceed with caution ...